FDAnews Device Daily Bulletin

House Oversight Committee Bears Down on Mylan for EpiPen ‘Monopoly’

Sept. 7, 2016

The House Oversight and Government Reform Committee is summoning Mylan CEO Heather Bresch to explain the company’s pricing practices for its EpiPen auto injector device.

The move follows other actions taken by four U.S. senators requesting information on the company’s price hikes for the emergency allergy auto-injector.

“Mylan has a virtual monopoly over the epinephrine auto-injector market,” an Aug. 29 letter to the CEO says. “While the medicine that actually stops an adverse reaction is remarkably cheap – only a few cents per dose – it is the delivery mechanism that is breaking the bank of Americans,” says the letter signed by Committee Chairman Jason Chaffetz and Ranking Member Elijah Cummings says. — Tamra Sami

View today's stories